Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma

Pituitary

Volumn 18, Issue 3, 2015, Pages 335-342

  Wu, Youtu ^a   Bai, Jiwei ^b   Li, Zhenye ^a   Wang, Fei ^a   Cao, Lei ^a   Liu, Chunhui ^a   Yu, Shengyuan ^a   Yu, Guoqiang ^a   Zhang, Yazhuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Methylation; Pituitary adenoma; sFRP4; Tumor suppressor

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; SFRP4 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOMA; ADOLESCENT; ADULT; AGED; CASE CONTROL STUDY; CELL LINE; COMPUTER ASSISTED TOMOGRAPHY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; WESTERN BLOTTING; YOUNG ADULT;

ADENOMA; ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84939892638     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-014-0579-4     Document Type: Article

References (44)

1. Melmed S (2008) Update in pituitary disease. J Clin Endocrinol Metab 93(2):331–338. doi:10.1210/jc.2007-1409
2. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195–208. doi:10.3171/jns.2002.96.2.0195
3. Popescu MN, Ionescu E, Iovanescu LC, Cotoi BV, Popescu AI, Ganescu AE, Glodeanu A, Geormaneanu C, Moraru A, Patrascu A (2013) Clinical aggression of prolactinomas: correlations with invasion and recurrence. Rom J Morphol Embryol 54(4):1075–1080
4. Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156(2):143–153. doi:10.1530/eje.1.02339
5. Cruciat CM, Niehrs C (2013) Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol 5(3):a015081. doi:10.1101/cshperspect.a015081
6. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. doi:10.1016/j.cell.2012.05.012
7. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1):9–26. doi:10.1016/j.devcel.2009.06.016
8. Herr P, Hausmann G, Basler K (2012) WNT secretion and signalling in human disease. Trends Mol Med 18(8):483–493. doi:10.1016/j.molmed.2012.06.008
9. Gueorguiev M, Grossman AB (2009) Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary 12(3):245–255. doi:10.1007/s11102-008-0147-x
10. Gueorguiev M, Grossman AB (2011) Pituitary tumors in 2010: a new therapeutic era for pituitary tumors. Nat Rev Endocrinol 7(2):71–73. doi:10.1038/nrendo.2010.233
11. Constantinou T, Baumann F, Lacher MD, Saurer S, Friis R, Dharmarajan A (2008) SFRP-4 abrogates Wnt-3a-induced beta-catenin and Akt/PKB signalling and reverses a Wnt-3a-imposed inhibition of in vitro mammary differentiation. J Mol Signal 3:10. doi:10.1186/1750-2187-3-10
12. Longman D, Arfuso F, Viola HM, Hool LC, Dharmarajan AM (2012) The role of the cysteine-rich domain and netrin-like domain of secreted frizzled-related protein 4 in angiogenesis inhibition in vitro. Oncol Res 20(1):1–6
13. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM (2011) Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 141(4):1486–1497. doi:10.1053/j.gastro.2011.06.047
14. Granados-Principal S, Quiles JL, Ramirez-Tortosa C, Camacho-Corencia P, Sanchez-Rovira P, Vera-Ramirez L, Ramirez-Tortosa MC (2011) Hydroxytyrosol inhibits growth and cell proliferation and promotes high expression of sfrp4 in rat mammary tumours. Mol Nutr Food Res 55(Suppl 1):S117–S126. doi:10.1002/mnfr.201000220
15. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H (2010) Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. Carcinogenesis 31(8):1381–1386. doi:10.1093/carcin/bgq082
16. Hrzenjak A, Tippl M, Kremser ML, Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD, Isadi-Moud N, Zatloukal K, Denk H (2004) Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 204(1):19–27. doi:10.1002/path.1616
17. O’Hurley G, Perry AS, O’Grady A, Loftus B, Smyth P, O’Leary JJ, Sheils O, Fitzpatrick JM, Hewitt SM, Lawler M, Kay EW (2011) The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology 59(6):1240–1248. doi:10.1111/j.1365-2559.2011.04073.x
18. Saran U, Arfuso F, Zeps N, Dharmarajan A (2012) Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol 13:25. doi:10.1186/1471-2121-13-25
19. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT (2005) Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65(16):7081–7085. doi:10.1158/0008-5472.can-05-0267
20. Qi J, Zhu YQ, Luo J, Tao WH (2006) Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol 12(44):7113–7117
21. Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Liu HS, Chu DW, Lin YW (2009) SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol 112(3):646–653. doi:10.1016/j.ygyno.2008.10.026
22. Choi JD, Lee JS (2013) Interplay between Epigenetics and Genetics in Cancer. Genomics Inform 11(4):164–173. doi:10.5808/gi.2013.11.4.164
23. Kinoshita T, Nomoto S, Kodera Y, Koike M, Fujiwara M, Nakao A (2011) Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology 58(107–108):1051–1056
24. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R (2006) Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 12(7 Pt 1):2109–2116. doi:10.1158/1078-0432.ccr-05-2468
25. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C (2006) CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 66(2):653–658. doi:10.1158/0008-5472.can-05-3712
26. Perry AS, O’Hurley G, Raheem OA, Brennan K, Wong S, O’Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D (2013) Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int J Cancer 132(8):1771–1780. doi:10.1002/ijc.27798
27. Kawakami K, Yamamura S, Hirata H, Ueno K, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M, Dahiya R (2011) Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer 128(3):541–550. doi:10.1002/ijc.25357
28. Zhang YW, Miao YF, Yi J, Geng J, Wang R, Chen LB (2010) Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma 57(3):228–233
29. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127(3):555–567. doi:10.1002/ijc.25083
30. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36(4):417–422. doi:10.1038/ng1330
31. Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC, Yu MH (2009) Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol 135(12):1665–1674. doi:10.1007/s00432-009-0613-5
32. Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, Lin YW (2013) Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol 28(3):551–559. doi:10.1111/jgh.12078
33. Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P, Aghajani A, Bondar IS, Omranipour R, Malekpour F, Mohajeri A, Babadi AJ, Sahin O, Bubnov VV, Najmabadi H, Hoheisel JD, Riazalhosseini Y (2012) Diagnostic values of GHSR DNA methylation pattern in breast cancer. Breast Cancer Res Treat 135(3):705–713. doi:10.1007/s10549-012-2197-z
34. Bu XM, Zhao CH, Zhang N, Gao F, Lin S, Dai XW (2008) Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. World J Gastroenterol 14(21):3421–3424
35. Kohno H, Amatya VJ, Takeshima Y, Kushitani K, Hattori N, Kohno N, Inai K (2010) Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep 24(2):423–431
36. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE (2010) Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma 51(9):1711–1719. doi:10.3109/10428194.2010.496505
37. Zlobec I, Terracciano L, Jass JR, Lugli A (2007) Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 451(4):763–769. doi:10.1007/s00428-007-0466-8
38. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262
39. Zhao P, Wang H, Gao H, Li C, Zhang Y (2013) Reversal of multidrug resistance by magnetic chitosan-Fe(3)O(4) nanoparticle-encapsulated MDR(1) siRNA in glioblastoma cell line. Neurol Res 35(8):821–828. doi:10.1179/1743132813y.0000000218
40. Becker G, Kocher M, Kortmann RD, Paulsen F, Jeremic B, Muller RP, Bamberg M (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178(4):173–186
41. Kopp C, Theodorou M, Poullos N, Astner ST, Geinitz H, Stalla GK, Meyer B, Molls M, Nieder C, Grosu AL (2013) Fractionated stereotactic radiotherapy in the treatment of pituitary adenomas. Strahlenther Onkol 189(11):932–937. doi:10.1007/s00066-013-0433-z
42. Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, Heinzelmann-Schwarz VA (2012) Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS ONE 7(2):e31885. doi:10.1371/journal.pone.0031885
43. Gotze S, Wolter M, Reifenberger G, Muller O, Sievers S (2010) Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 126(11):2584–2593. doi:10.1002/ijc.24981
44. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31(1):1–31. doi:10.3109/08977194.2012.752737